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Purpose: To compare the short term effects of topical 0.05% cyclosporine (CsA) and a mixture of 0.08% 
chondroitin sulfate and 0.06% sodium hyaluronate (CS-HA) on dry eye ocular surfaces.
Methods: 36 patients with moderate to severe dry eye (5 mm/5 min or less with Schirmer's test or tear 
break up time (BUT) less than 6 seconds), were treated with topical application of CS-HA on one eye and 
CsA on the other 4 times a day for 6-8 weeks. BUT, Schirmer's test without anesthesia, and conjunctival 
impression cytology (CIC; goblet cell density, nucleus to cytoplasmic ratio, and epithelial cell morphology) 
were evaluated and compared between eyes before and after treatment (repeated measurement of ANOVA).
Results: After treatment, BUT and tear wettings were significantly prolonged in each group. Topical CsA 
treated eyes had greater increase in BUT (p=0.026); there was no significant difference in tear wetting 
(p=0.132). While the 3 parameters of CIC improved in both groups, goblet cell density was significantly 
higher in eyes treated with CsA (p=0.033).
Conclusions: While both CS-HA and 0.05% CsA eyedrops improve ocular surfaces, topical CsA may have 
a better effect on enhancing tear film stability and goblet cell density. 
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Dry eye is a tear film disorder caused by tear deficiency 
or excessive evaporation, and is associated with ocular 
discomfort, dryness, scratchiness, burning, soreness, and 
grittiness.
1 Objective signs of ocular surface damage include 
tear film instability and tear hyperosmolarity.
2
In recent years, there has been growing evidence that 
inflammation and apoptosis of the ocular surface has a key 
role in the development of dry eye.
3,4 In addition, 
inflammatory cytokines such as interleukin (IL)-1 α, IL-8, 
and tumor necrosis factor-α, and immune-activation marker 
expression, such as HLA-DR, intracellular adhesion molecule-1, 
and CD11 a, are increased in dry eyes.
4,5 This chronic 
inflammatory environment is partly responsible for the 
characteristic conjunctival epithelium pathologic alterations, 
such as squamous metaplasia and goblet cell loss.
6
Therefore, recent trends in KCS treatment have been 
aimed at improving ocular surfaces by suppressing apoptosis 
and conjunctival epithelium and goblet cell inflammation.
7
Topical cyclosporine A (CsA) has been reported to 
decrease immune- and apoptosis-related markers,
8 improve 
aqueous tear production,
9 increase conjunctival goblet cell 
density,
4 and have a therapeutic effect on various ocular 
surface diseases.
10
Similarly, topical sodium hyaluronate (HA) has been 
reported to suppress apoptosis-related and inflammatory 
markers (Fas, Apo 2.7, HLA-DR and CD 40), upregulate 
protective markers (MUC5AC and CD63),
8 and increase 
goblet cell density and aqueous tear production.
11,12 
Chondroitin sulfate (CS), used as a lubricant,
12 has also been 
reported to have anti-inflammatory effects.
13
Although topical CsA and CS-HA have anti-inflammatory 
and apoptosis-suppressing effects, no study has compared 
these two preparations. The purpose of this study was to 
investigate and compare the short term effects of topical 
CS-HA and CsA on the ocular surfaces of dry eye patients.Kor J Ophthalmol Vol.21, No.4, 2007
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Materials and Methods
Patient characteristics 
Informed consent was obtained from all subjects, and the 
study was approved by our institutional review board. 
Forty-seven consecutive patients with bilateral moderate to 
severe dry eye were enrolled prospectively. The female- 
to-male ratio was 38:9. Age distribution was 49.31±11.38 
years. Moderate to severe dry eye disease was defined by: 
(1) Schirmer's test reading without anesthesia of less than or 
equal to 5 mm / 5 min
14; or (2) 3 tear film BUT all less 
than 6 seconds.
15 Topical 0.08% chondroitin sulfate (CS) 
mixed with 0.06% sodium hyaluronate (HA) was applied on 
one eye and 0.05% cyclosporine (CsA) on the other eye four 
times a day for 6-8 weeks. There was at least a 2-week 
washout phase before starting treatment to eliminate previous 
effects of artificial tears. The mean application was 48.37±
9.61 days. In this period, compliance was evaluated by 
telephone interview and was found to be similar between the 
two eyedrops. Poor compliance was found in 11 participants, 
who were excluded from the study.
We excluded patients who reported topical or systemic 
CsA or ophthalmic steroids use within the previous 90 days 
or 3 weeks, respectively. Other reasons for exclusion 
included previous punctual plug, contact lens wear, use of 
other topical treatments, active ocular infection, severe 
blepharitis, recurrent herpes keratitis within the previous 6 
months, anterior segment surgery or trauma within the 
previous 12 months, punctuate epithelial erosions involving 
more than one third of the cornea, other ocular surface 
diseases, or non-KCS inflammation, including atopic 
keratoconjunctivitis.
Eyedrop Preparation
CS-HA and CsA eyedrops were prepared at Seoul National 
University Hospital pharmacy under sterile conditions. 
CS-HA eyedrops were made by diluting 0.75 ml Viscoat
Ⓡ (a 
1:3 mixture of 4% CS and 3% HA; Alcon Surgical, Inc., Fort 
Worth, TX) in 35 ml normal saline, producing topical 
viscoelastics containing 0.08% CS and 0.06% HA (CS-HA 
eyedrops). CsA eye drops were made by mixing Neoral
Ⓡ 
Soft Gelatin Capsules (Novartis, Japan) containing 100 mg of 
micro-emulsified cyclosporine (1 ml) with 19 ml balanced 
salt solution (BSS
Ⓡ, Alcon Surgical, Inc., Fort Worth, TX), 
producing topical 0.5% CsA.; 9 ml balanced salt solution 
was added to 1 ml of 0.5% CsA to make 0.05% 
eyedrops. Preparations were maintained regularly to avoid 
contamination and loss of efficacy. 
Monitoring effects of topical eyedrops
Tear film break-up time (BUT), Schirmer test without 
anesthesia, and conjunctival impression cytology (CIC) were 
performed before and after scheduled instillation (mean 
interval: 48.37±9.61 days). The examiner was blind to 
eyedrop type. Tear film BUT was measured three times to 
calculate a mean value. Schirmer's test without anesthesia 
was performed using standard strips (Alcon, Fort Worth, 
Texas, USA) in the lower conjunctival sac for 5 minutes. 
CIC was performed as follows. After topical anesthesia with 
0.5% proparacaine hydrochlororide (Alcaine
Ⓡ, Alcon- 
Couvreur, Puurs, Belgium), MF Millipore membrane filters 
with 0.22 μm pores were applied to the temporal bulbar 
conjunctiva. To guarantee the correct staining surface, 
the membrane filter was cut into 5×5 mm asymmetrical 
pieces with a pointed tip in one corner. Using an 
ophthalmodynanometer, 60 g of gentle pressure was applied 
to the filter for 5 seconds; the membrane was fixed in 95% 
ethanol, stained with periodic acid-Schiff, dehydrated in 
ethanol (70, 80, 90, 100% in sequence) and xylene (80, 90, 
100% in sequence), and then coverslipped. Using 400 
magnification optical microscopy goblet cell densities (GCD), 
nucleus to cytoplasm ratios (NCR) and epithelial cell 
morphology (ECM) were evaluated. GCD was averaged for 
every 100 epithelial cells in five high-power fields (HPF, 
×400 magnification) in each eye. NCR and ECM, graded 
according to Saini et al.
16 were defined as the average value 
for five HPF in each eye.
Statistical analysis
Statistical analysis was performed using SPSS for 
Windows version 11.5 (SPSS, Chicago, IL, USA). To 
compare therapeutic effects between eyedrops, ANOVA was 
used. P<0.05 was considered significant in all statistical 
testing.
Results
Tear film BUT
Before eyedrop application, there was no significant 
difference of tear film BUT between each group of eyes 
(4.19±0.86 seconds on CS-HA-treated eyes and 4.08±1.01 
seconds on CsA-treated eyes, p=0.623). After scheduled 
applications, there was significant prolongation of tear film 
BUT in both groups (4.39±1.12 sec on CS-HA-treated eyes 
and 5.08±0.77 on CsA-treated eyes), (p=0.041 and 0.029, 
respectively). BUT increase was more prominent in the CsA 
group than in the CS-HS group (p=0.026, Fig. 1).
Schirmer‘s test
There was no significant difference of aqueous tear 
production between the two groups before treatment (5.72±
1.72 seconds on topical CS-HA treated eyes and 6.17±1.56 
seconds on topical CsA treated eyes) (p=0.234). Tear wetting 
increased significantly in both groups compared with JW Moon, et al. TOPICAL CYCLOSPORINE AND VISCOELASTIC IN DRY EYE
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Fig. 2. Comparing aqueous tear production (Schirmer's test) 
between eyes before and after topical application of 0.077% 
chondroitin sulfate with 0.06% hyaluronate (on right eyes) and
0.05% cyclosporine (on left eyes). After treatment with the 
assigned eyedrop, aqueous production increased significantly
in both eyes. The amount of increase in both eyes was similar.
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BUT: tear film break-up time.
Pre/Post: beforeand aftertreatmen, respectively.
ΔChanges: the amount of changes after application of the eye drop.
CS-HA: topical0.% ondroitin sulfate with 0.0% hyaluronat.
CsA: topical 0.05% cyclosporine
* repeated measurement of ANOVA.
Fig. 1. Comparing tear film BUT between eyes before and 
after topical application of topical 0.077% chondroitin sulfate 
with 0.06% hyaluronate (on right eyes) and 0.05% 
cyclosporine (on left eyes). Before treatment, there was no 
significant difference between eyes. After applications, tear 
film BUT increased significantly in both eyes but was more 
profound in left eyes.
pretreatment levels (6.47±1.68 seconds on topical CS-HA 
treated eyes and 7.17±1.56 seconds on topical 0.05 % CsA 
treated eyes), (p=0.024 and 0.011, respectively). Although the 
amount of tear wetting tended to be greater in the 0.05% CsA 
group, there was no statistically significant difference 
between the two groups (p=0.132) (Fig. 2).
Conjunctival impression cytology
Before treatment, mean GCD, NCR, and ECM were 5.36
±1.02, 3.27±0.97, and 4.25±0.61 in topical CS-HA treated 
eyes and 5.47±1.71, 3.53±0.61, and 4.59±0.78 in topical 
CsA treated eyes, respectively with no significant difference 
between the two groups (p=0.795, 0.333, and 0.688, 
respectively). After scheduled treatment with topical CS-HA, 
there was significant improvement of GCD, NCR, and ECM 
(p=0.047, 0.035, and 0.018, respectively) (Fig. 3, 4, 5). 
Similarly, there was marked improvement of GCD, NCR, and 
ECM in topical CsA treated eyes (p=0.012, 0.025, and 0.027, 
respectively) (Fig. 3, 4, 5). GCDs increased more 
prominently in topical CsA treated eyes than in topical 
CS-HA treated eyes (p=0.033), while NCR and ECM showed 
no significant difference (p=0.721 and 0.439, respectively) 
(Fig. 3, 4, 5).
Discussion
Conjunctival goblet cell densities are sensitive indicators of 
ocular surface disease. In dry eyes, the first evidence of 
surface injury is the manifestation of decreased conjunctival 
goblet cells.
17 The results of this study suggest that topical 
CS-HA and 0.05% CsA stabilize tear film instability, increase 
aqueous tear production, and also improve ocular surfaces; 
these results are consistent with previous studies.
18
Kunert et al. reported that topical 0.05% CsA increased 
conjunctival goblet cell density and decreased epithelial 
turnover after 6 months of application.
4 Strong et al. also 
demonstrated that topical CsA significantly reduced 
conjunctival epithelial apoptosis and protected against goblet 
cell loss in experimental murine keratoconjunctivitis sicca.
19 
However, the novelty of this study is that 0.05% CsA 
eyedrops increased conjunctival goblet cell density and tear 
film stability more effectively than CS-HA. This result can 
be explained as follows. Ocular surface mucin, consisting 
predominantly of conjunctival goblet cell secretions, adheres 
to conjunctival and corneal epithelial cells glycocalyces and 
enhances corneal wettability by serving as an interface 
between the hydrophobic corneal epithelium and aqueous tear 
fluid. We believe that mucin increases with increased goblet 
cell density, which was enhanced by topical cyclosporine. 
This explanation is also supported by Moore et al.; they 
found that topical cyclosporine restored in vivo dog 
conjunctival mucin stores to control levels over a 4-week 
period.
20
Commercial topical cyclosporine was not available in our 
country at the start of the study, and was difficult to prepare 
due to hydrophobicity (log P=3.0) and low aqueous solubility 
(6.6 ug/ml).
21,22Kor J Ophthalmol Vol.21, No.4, 2007
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Fig. 4. Before topical eyedrops, nucleus to cytoplasmic ratios 
(NCR) of conjunctival impression cytology were similar 
between the two groups. After assigned treatments (topical 
chondroitin sulfate with sodium hyaluronate (CS-HA) for right 
eyes and topical cyclosporine (CsA) for left eyes), there was 
significant NCR improvement in both eyes. There was no 
significant differences among treatment groups.
2
4
6
8
pre post pre post CS-HA CsA
Δ changes 
p
*=0.047
p
*=0.012
p
†=0.033
G
o
b
l
e
t
 
c
e
l
l
 
d
e
n
s
i
t
y
‡
 
CS-HA  CsA 
Pre/Post: before and after treatment, respectively.
ΔChanges : the amount of changes after application of the eyedrop.
CS-HA: topical 0.08% chondroitin sulfate with 0.06% hyaluronate.
CsA: topical 0.05% cyclosporine.
* repeated measurement of ANOVA.
†averaged per 100 epithelial cells in 5 high-power fields (×400).
Fig. 3. Before treatment with topical eyedrops, goblet cell 
densities (GCD) were similar between eyes. After assigned 
treatments (topical chondroitin sulfate with sodium hyaluronate
(CS-HA) for right eyes and topical cyclosporine (CsA) for left
eyes), there was a significant GCD increase in both eyes. 
However, GCD increase was greater in left eyes.
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Fig. 5. Before treatments, epithelial morphologies (ECM) of 
conjunctival epithelium in conjunctival impression cytology 
were similar between eyes. While there was significant ECM
improvement in both eyes after treatments (topical chondroitin
sulfate with sodium hyaluronate (CS-HA) for right eyes and 
topical cyclosporine (CsA) for left eyes), the degree of change
in both eyes was similar.
We prepared 0.05% topical CsA by mixing CsA capsule 
contents (Neoral
Ⓡ Soft Gelatin Capsule, Novartis) with a 
balanced salt solution. In this capsule, CsA is dissolved in 
ethanol with corn oil-mono-di-triglycerides, propylene glycol 
(an enhancer of tissue permeation by supersaturation systems, 
based on increased thermodynamic activity), and polyoxyl 40 
hydrogenated castor oil (a pharmaceutical aid (nonionic 
surfactant) used to improve solubilization). Propylene glycol 
is tissue permeation enhancer by supersaturation systems. 
Kuwano et al. demonstrated that CsA solubility into aqueous 
formulations containing polyoxyl 40 hydrogenated castor 
oil.
23 In an aqueous medium with nonionic surfactant, 
micelles are formed, allowing CsA to dissolve in them. As 
micelle size is smaller than emulsion droplets, with a mean 
diameter of 200 nm, they have a larger surface area, enabling 
more drug binding. Therefore, more CsA can be released for 
ocular surface delivery. This may explain the early 
therapeutic effects of topical CsA. The main downside to our 
preparation was a stinging sensation in patients with moderate 
epithelial erosion, possibly caused by sub-appropriate pH. 
Therefore, we limited 0.05% CsA application to patients 
without epithelial defect or erosions involving more than one 
third of the cornea.
Topical eyedrops containing 0.08% CS and 0.06% HA 
were prepared by diluting commercial viscoelastic material in JW Moon, et al. TOPICAL CYCLOSPORINE AND VISCOELASTIC IN DRY EYE
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normal saline. The diluting concentration was determined 
from previous reports.
12,24
Topical application of HA has been shown to result in 
both subjective and objective improvements.
13,25 Several 
mechanisms have been suggested. HA is a natural biopolymer 
and its concentration increases in response to ocular damage 
and corneal wound healing.
26 In vitro HA promotes cell 
migration and stabilizes the ocular surface epithelial 
barrier,
27,28 suggesting intrinsic wound healing properties. 
Binding of HA to CD44, a corneal and conjunctival cell 
receptor,
29 may promote cell adhesion and motility via 
cytoskeletal protein action,
30 stimulate cell proliferation 
through a kinase cascade mechanism,
31 and enhance rabbit 
corneal epithelial cell growth in vitro.
32 Interestingly, it has 
been reported that CD44 is expressed in 30-50% of 
conjunctival epithelial cells in patients with moderate dry eye, 
and that HA is associated with decreased expression.
8 
Apoptosis-related and inflammatory markers (Fas, Apo 2.7, 
HLA-DR, and CD40) tend to decrease and potentially 
protective markers (MUC5AC and CD63) tend to increase 
with HA application.
8
HA also increases precorneal tear film stability, which 
protects the ocular surface from environmental agents
11 and has 
water retentive properties improving wettability.
33 Therefore, 
HA may contribute to a favorable microenvironment during 
blinking and ocular movements.
In our study, squamous metaplasia on CIC improved after 
treatment with CS-HA eyedrops for 48.37±9.61 days. The 
recovery time of patients in our study seems to be shorter 
than that of previous reports of 8 weeks or more.
34 This 
discrepancy can be explained by the synergistic anti- 
inflammatory effect of CS. CS is known to downregulate 
gene expression and synthesis of nitric oxide synthase and 
prostaglandin E2 production,
35 components of the inflammatory 
cascade, and induce IL-1β, an inducing factor for lacrimal 
gland cell death.
35 As IL-1β and matrix metalloproteinase-9, 
a physiological activator of IL-1β, are significantly elevated 
in tear fluid and conjunctival epithelium of dry eyes,
36,37  the 
suppressive effects of CS can enhance HA effects to improve 
ocular surfaces.
Given the immediate symptomatic improvements and 
synergistic anti-inflammatory effects of topical CS-HA, it can 
be recommended that topical CS-HA be simultaneously 
administered with CsA, which may require longer treatment 
to suppress apoptosis. Additionally, as HA and topical CsA 
have similar effects via the different aforementioned 
mechanisms, it is possible that HA might act synergistically 
with topical CsA; further investigation would be helpful.
CS-HA and CsA eyedrops were mixed with normal saline 
and a balanced salt solution, respectively, which may have 
had effects on ocular surfaces or tear production. Because a 
vehicle-treated control group was not included, this 
perspective cannot be evaluated. Another limitation is the 
inability to demonstrate the effects of CS-HA or CsA on each 
patient's other eye, which may have been mediated by the 
neural loop of the ocular surface lacrimal functional unit.
Conclusion
This study suggests that, while topical applications of 
CS-HA and CsA are effective for dry eye, topical CsA may 
have a greater effect on the improvement of conjunctival 
GCD, which can enhance tear film stability, compared with 
topical CS-HA.
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